Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
FDA approves anti-obesity drug as first sleep apnea medication
The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment of the disorder.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Lilly's Zepbound to be covered by Medicare for sleep apnea
Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep apnea in people with obesity. CNBC said Wednesday that the U.S. Centers for Medicare & Medicaid Services confirmed that Medicare drug plans can now cover Zepbound,
Yahoo19d
FDA approves weight-loss drug to treat sleep apnea
and obesity. “Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour, director of the Division of Pulmonology ...
Honolulu Star-Advertiser19d
New weight-loss treatment becomes first FDA-approved drug for sleep apnea
The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the ...
Benzinga.com18d
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA’s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA. “Too often, OSA is brushed off as ‘just ...
KOAT Albuquerque20d
FDA says knockoff versions of Lilly obesity drug must come off the market
Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity ... they pay.Zepbound is FDA-approved to treat obesity and Mounjaro is ...
The Washington Post20d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss ... likely opens the door to Medicare coverage of an anti-obesity medication a bit wider than when the FDA ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
For people with obstructive sleep apnea, Zepbound should be used with a reduced-calorie diet and increased physical activity, drugmaker Eli Lilly said. The US Food and Drug Administration on Friday ...